180 Life Sciences’ (ATNF) Sell (E+) Rating Reaffirmed at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Performance

NASDAQ ATNF opened at $0.94 on Friday. The business has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $1.47. 180 Life Sciences has a fifty-two week low of $0.66 and a fifty-two week high of $17.75.

180 Life Sciences (NASDAQ:ATNF) last released its earnings results on Thursday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Investors Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC bought a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences at the end of the most recent reporting period. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.